Dry Age-Related Macular Degeneration Market to hit USD 10.57 billion by 2032 at a CAGR of 9.1%.
The dry age-related macular degeneration market is expected to boom, considering an array of factors that include new products and a strong product pipeline. The mounting incidence of AMD, especially in geriatric populations, would catapult the market in this space. In 2022, Americans aged 65 and older numbered 58 million. By 2050, this number is expected to reach 82 million, up substantially by 47%. This demographic shift accentuates the ever-growing requirement for treatments of dry age-related macular degeneration owing to the advanced age at an unprecedented rate in the U.S. population.